Aspen Neuroscience closed a $115 million Series C to advance its autologous cell therapy programs for Parkinson’s disease and accelerate an expected Phase III start next year. The financing, which includes strategic backing, replenishes cash for late‑stage development and potential IPO plans. Aspen’s lead autologous regenerative candidate aims to restore dopaminergic function; management signaled readiness to expand trials and prepare regulatory interactions for Phase III. The cash infusion follows prior positive signals that supported deeper clinical testing. The round highlights investor appetite for cell therapies in neurodegeneration while underscoring the capital intensity of autologous programs and the need for robust clinical readouts to justify broader commercialization and public markets.